PDS Biotechnology ( (PDSB) ) has issued an update.
PDS Biotechnology Corporation has reported promising results from the VERSATILE-002 Phase 2 clinical trial of their immunotherapy, Versamune® HPV, combined with KEYTRUDA® for treating HPV16-positive head and neck cancer, showing a median overall survival of 30 months and a disease control rate of 77%. With 21% of patients experiencing significant tumor shrinkage, the company is gearing up to start the VERSATILE-003 Phase 3 trial within the year, bolstering hopes for a new effective treatment option for this patient demographic.
For detailed information about PDSB stock, go to TipRanks’ Stock Analysis page.
